These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25892404)

  • 1. A risk score for no reflow in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention.
    Wang JW; Zhou ZQ; Chen YD; Wang CH; Zhu XL
    Clin Cardiol; 2015 Apr; 38(4):208-15. PubMed ID: 25892404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a clinical risk score predicting the no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Wang JW; Chen YD; Wang CH; Yang XC; Zhu XL; Zhou ZQ
    Cardiology; 2013; 124(3):153-60. PubMed ID: 23485798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation of serum uric acid levels with coronary flow in patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention].
    Wang JW; Chen YD; Wang CH; Zhu XL
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(44):3100-3. PubMed ID: 23328417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of the TIMI risk index on admission for predicting angiographic no-reflow after primary percutaneous coronary intervention in patients with STEMI.
    Acet H; Ertaş F; Akil MA; Bilik MZ; Aydin M; Polat N; Yildiz A
    Turk J Med Sci; 2016 Apr; 46(3):604-13. PubMed ID: 27513233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal extent of lipid pool assessed by optical coherence tomography predicts microvascular no-reflow after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Ikenaga H; Ishihara M; Inoue I; Kawagoe T; Shimatani Y; Miura F; Nakama Y; Dai K; Ohtani T; Ohi K; Miki T; Nakamura M; Kishimoto S; Sumimoto Y; Kihara Y
    J Cardiol; 2013 Aug; 62(2):71-6. PubMed ID: 23680004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Celık T; Balta S; Demır M; Yıldırım AO; Kaya MG; Ozturk C; Demırkol S; Unlu M; Kılıc S; Aydın İ; Iyısoy A
    Cardiol J; 2016; 23(1):84-92. PubMed ID: 26503078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting no-reflow phenomenon prior to primary percutaneous coronary intervention using a novel probability risk score derived from clinical and angiographic parameters.
    Stajic Z; Milicevic D; Kafedzic S; Aleksic A; Cerovic M; Tasic M; Andjelkovic Apostolovic M; Ignjatovic A; Zornic N; Obradovic G; Jovanovic V; Jagic N; Neskovic AN; Davidovic G
    Eur Rev Med Pharmacol Sci; 2022 Feb; 26(3):759-770. PubMed ID: 35179742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of no-reflow and major adverse cardiovascular events with a new scoring system in STEMI patients.
    Bayramoğlu A; Taşolar H; Kaya A; Tanboğa İH; Yaman M; Bektaş O; Günaydın ZY; Oduncu V
    J Interv Cardiol; 2018 Apr; 31(2):144-149. PubMed ID: 29193382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New CHA
    Zhang QY; Ma SM; Sun JY
    BMC Cardiovasc Disord; 2020 Jul; 20(1):346. PubMed ID: 32711475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SYNTAX score is a predictor of angiographic no-reflow in patients with ST-elevation myocardial infarction treated with a primary percutaneous coronary intervention.
    Şahin DY; Gür M; Elbasan Z; Kuloğlu O; Şeker T; Kivrak A; Tanboğa İH; Gözübüyük G; Kirim S; Çayli M
    Coron Artery Dis; 2013 Mar; 24(2):148-53. PubMed ID: 23363986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of NT-proBNP on admission for early risk stratification of patients undergoing primary percutaneous coronary intervention.
    Ayhan E; Isık T; Uyarel H; Ergelen M; Cicek G; Ozyurtlu F; Ghannadian B; Tanboga IH
    Kardiol Pol; 2013; 71(2):165-75. PubMed ID: 23575711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The impact of pre-primary percutaneous coronary intervention β blocker use on the no-reflow phenomenon in patients with acute myocardial infarction].
    Wang J; Chen Y; Wang C; Zhu X
    Zhonghua Xin Xue Guan Bing Za Zhi; 2014 Oct; 42(10):822-6. PubMed ID: 25547444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between neutrophil counts on admission and angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
    Wang Z; Ren L; Lei L; Ye H; Peng J
    Acta Cardiol; 2016 Apr; 71(2):241-6. PubMed ID: 27090048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients who underwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction.
    Kurtul A; Yarlioglues M; Celik IE; Duran M; Elcik D; Kilic A; Oksuz F; Murat SN
    Coron Artery Dis; 2015 Dec; 26(8):706-12. PubMed ID: 26340546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial infarction.
    Jeong YH; Kim WJ; Park DW; Choi BR; Lee SW; Kim YH; Lee CW; Hong MK; Kim JJ; Park SW; Park SJ
    Int J Cardiol; 2010 May; 141(2):175-81. PubMed ID: 19144424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of initial and residual thrombus burden on the no-reflow phenomenon in patients with ST-segment elevation myocardial infarction.
    Ahn SG; Choi HH; Lee JH; Lee JW; Youn YJ; Yoo SY; Cho BR; Lee SH; Yoon J
    Coron Artery Dis; 2015 May; 26(3):245-53. PubMed ID: 25503419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of syntax score and syntax score II to predict "no reflow phenomenon" in patients with ST-segment elevation myocardial infarction.
    Yesin M; Çağdaş M; Kalçık M; Uluganyan M; Efe SÇ; Rencüzoğulları İ; Karabağ Y; Gürsoy MO; Karakoyun S
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1883-1889. PubMed ID: 28664479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of no-reflow phenomena after primary percutaneous coronary intervention: a time-dependent analysis of mortality.
    Choo EH; Kim PJ; Chang K; Ahn Y; Jeon DS; Lee JM; Kim DB; Her SH; Park CS; Kim HY; Yoo KD; Jeong MH; Seung KB
    Coron Artery Dis; 2014 Aug; 25(5):392-8. PubMed ID: 24625688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Aitmokhtar O; Paganelli F; Benamara S; Azaza A; Bonello L; Hamza O; Seddiki S; Benathmane T; Saidane M; Bouzid A; Kara M; Sik A; Azzouz A; Harbi F; Monsuez JJ; Benkhedda S
    Arch Cardiovasc Dis; 2017 Nov; 110(11):626-633. PubMed ID: 28583820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Yang L; Cong H; Lu Y; Chen X; Liu Y
    Medicine (Baltimore); 2020 Jun; 99(26):e20152. PubMed ID: 32590726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.